Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.
Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.
The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.
Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.